Black Rock Inc. Galectin Therapeutics Inc Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GALT
# of Institutions
103Shares Held
10.1MCall Options Held
587KPut Options Held
2.02M-
Vanguard Group Inc Valley Forge, PA2.19MShares$5.24 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$2.92 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$2.04 Million0.0% of portfolio
-
Geneos Wealth Management Inc.423KShares$1.01 Million0.02% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$952,1130.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $142M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...